Abstract is: Imipenem/cilastatin, sold under the brand name Primaxin among others, is an antibiotic useful for the treatment of a number of bacterial infections. It is made from a combination of imipenem and cilastatin. Specifically it is used for pneumonia, sepsis, endocarditis, joint infections, intra-abdominal infections, and urinary tract infections. It is given by injection into a vein or muscle. Common side effects include nausea, diarrhea, and pain at the site of injection. Other side effects may include Clostridium difficile diarrhea and allergic reactions including anaphylaxis. It is unclear if use during pregnancy is safe for the baby. Imipenem is in the carbapenem family of medications and works by interfering with the bacteria's cell wall. Cilastatin blocks the activity of dehydropeptidase I which prevents the breakdown of imipenem. Imipenem/cilastatin was first sold in 1987. It is on the World Health Organization's List of Essential Medicines.
type of mixture of chemical entities | Q119892838 |
combination drug | Q1779868 |
P527 | has part(s) | cilastatin | Q418201 |
imipen | Q425152 | ||
P366 | has use | medication | Q12140 |
P8026 | LiverTox likelihood score | LiverTox toxicity likelihood category D | Q83284515 |
P3489 | pregnancy category | US pregnancy category C | Q28123617 |
P2868 | subject has role | essential medicine | Q35456 |
P12081 | WHO Aware Classification | watch | Q122925721 |
Q61924658 | A De-Escalating Strategy for Antibiotic Treatment of Pneumonia in The Medical Intensive Care Unit (0787B-092) |
Q63596610 | Antibacterial Prophylaxis vs no Prophylaxis for Hematological Malignancies Patients Before Allo-HSCT |
Q63600004 | DetectAB - Detecting Antibiotics |
Q113898389 | Efficacy and Safety of Colistin Based Antibiotic Therapy |
Q63338822 | Ertapenem Versus Meropenem/Imipenem for ESBL+ Gram-negative Infections |
Q63402258 | Evaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections |
Q113932271 | Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With cUTI Including AP (EudraCT no. 2022-000061-40) |
Q113932276 | Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Recarbrio in Adults With HABP /VABP (EudraCT no. 2022-000081-18) |
Q113895218 | Evidence Based Management of Acute Biliary Pancreatitis |
Q61980590 | Fosfomycin Plus Imipenem for Treatment of Infective Endocarditis |
Q62030827 | Imipenem in Critically Ill Patients |
Q113914561 | Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections |
Q63571684 | Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (MK-7655A-016) |
Q113914265 | Imipenem/Cilastatin/Relebactam PK in ECMO |
Q113916561 | Intrapulmonary Pharmacokinetics of XNW4107, Imipenem and Cilastatin in Healthy Subjects |
Q113919489 | PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN |
Q113911874 | Pharmacokinetics of XNW4107 in Subjects With Various Degrees of Renal Function |
Q61924812 | Resistance Rates and Mechanisms of Resistance to Imipenem and Meropenem at UPMC |
Q63582084 | Second-generation Sequencing Guides the Treatment of Severe Pneumonia |
Q61957076 | Study of the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for the Treatment of Complicated Urinary Tract Infection (cUTI) (MK-7655-003) |
Q61956969 | Study of the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone to Treat Complicated Intra-Abdominal Infection [cIAI] (MK-7655-004) |
Q63579665 | Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex |
Q62811153 | Temocillin Versus a Carbapenem as Initial Intravenous Treatment for ESBL Related Urinary Tract Infections |
Q63572632 | The Analysis of Factors Influencing the Vd of Imipenem in Septic Shock Patients |
Q113913810 | To Evaluate the Pharmacokinetics of XNW4107 in Healthy Adult Young Females and in Healthy Adult Elderly Males and Females. |
Q59333884 | 1339. Results for the Supplemental Microbiological Modified Intent-to-Treat (SmMITT) Population of the RESTORE-IMI 1 Trial of Imipenem/Cilastatin/Relebactam (IMI/REL) vs. Imipenem/Cilastatin Plus Colistin (IMI+CST) in Patients with Imipenem-Nonsuscep |
Q59328784 | 1951. Nephrotoxicity Associated With Imipenem/Cilastatin/Relebactam (IMI/REL) vs. Imipenem/Cilastatin Plus Colistin (IMI+CST) in Patients With Imipenem-Nonsusceptible (NS) Bacterial Infections |
Q89864905 | A Comparison of Treatment Outcomes Between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem/Cilastatin/Relebactam Versus Colistin Plus Imipenem/Cilastatin in Patients With Imipenem-Nonsusceptible Bacterial Infections |
Q42677494 | A Multicenter Comparative Study of Meropenem and Imipenem/Cilastatin in the Treatment of Complicated Urinary Tract Infections in Hospitalized Patients |
Q44398805 | A Retrospective Study on the Incidence of Seizures among Neurosurgical Patients Who Treated with Imipenem/Cilastatin or Meropenem |
Q40072736 | A carbapenem antibiotic imipenem/cilastatin induces an oxidative stress-status and gonadotoxic effects in « wistar » rats |
Q40694715 | A case of severe pneumonia in an elderly man, caused by Citrobacter freundii suspected to have a low susceptibility to imipenem/cilastatin sodium |
Q68014789 | A clinical phase I study on intramuscular imipenem/cilastatin sodium |
Q81540974 | A clinical study of imipenem/cilastatin in the treatment of generalized and localized infections |
Q44723269 | A clinical study on imipenem/cilastatin sodium in the field of pediatrics |
Q40779841 | A comparative study of ceftriaxone plus amikacin, ceftazidime plus amikacin and imipenem/cilastatin in the empiric therapy of febrile granulocytopenic cancer patients |
Q40695798 | A comparative study of imipenem/cilastatin sodium BID vs QID in the treatment of infections associated with hematopoietic disorders |
Q45286739 | A comparison of imipenem/cilastatin with the combination of cefuroxime and metronidazole in the treatment of intra-abdominal infections |
Q24813784 | A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]. |
Q60310408 | A multicenter, double-blind, randomized, comparison study of the efficacy and safety of tigecycline to imipenem/cilastatin to treat complicated intra-abdominal infections in hospitalized subjects in China |
Q42935997 | A multicenter, randomized controlled clinical study on biapenem and imipenem/cilastatin injection in the treatment of respiratory and urinary tract infections |
Q70395125 | A multiclinic randomized study of the comparative efficacy, safety and tolerance of imipenem/cilastatin and moxalactam |
Q90924998 | A novel analytical method to assess the effect of imipenem/cilastatin on liver function laboratory indexes in Chinese underage inpatients: Probability distribution curve |
Q40491154 | A novel chitosan-polyethylene oxide nanofibrous mat designed for controlled co-release of hydrocortisone and imipenem/cilastatin drugs |
Q80282088 | A post hoc subgroup analysis of meropenem versus imipenem/cilastatin in a multicenter, double-blind, randomized study of complicated skin and skin-structure infections in patients with diabetes mellitus |
Q72956657 | A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study Group |
Q43834733 | A randomized, controlled clinical trial of meropenem and imipenem/cilastatin in the treatment of acute bacterial infections |
Q44352883 | A randomized, controlled clinical trial on meropenem versus imipenem/cilastatin for the treatment of bacterial infections |
Q72479622 | A serial application study on twice daily dose of imipenem/cilastatin in patients undergoing slow hemodialysis |
Q24601509 | Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants |
Q53744779 | Aerosolization of imipenem/cilastatin prevents pseudomonas-induced acute lung injury. |
Q40605272 | An open, randomised, multi-centre study comparing the safety and efficacy of sitafloxacin and imipenem/cilastatin in the intravenous treatment of hospitalised patients with pneumonia |
Q44621628 | Basic and clinical studies on imipenem/cilastatin sodium in the pediatric field |
Q53993909 | Biapenem versus imipenem/cilastatin in the treatment of complicated intra-abdominal infections: report from a Swedish Study Group. |
Q28305833 | Carbapenems, a new class of beta-lactam antibiotics. Discovery and development of imipenem/cilastatin |
Q45111890 | Cefazolin plus ceftazidime versus imipenem/cilastatin monotherapy for treatment of CAPD peritonitis--a randomized controlled trial. |
Q41255069 | Ceftriaxone versus imipenem/cilastatin as empirical monotherapy for infections in cancer patients |
Q35649855 | Cerebrospinal fluid penetration of imipenem and cilastatin (primaxin) in children with central nervous system infections |
Q42274517 | Cholestasis in imipenem/cilastatin treatment |
Q68047623 | Clearance of imipenem/cilastatin in acute renal failure patients treated by continuous hemodiafiltration (CAVHD) |
Q43988234 | Clinical and pharmacokinetic evaluation of imipenem/cilastatin sodium in children |
Q34508279 | Clinical and pharmacokinetic study of imipenem/cilastatin in children and newborn infants |
Q43553822 | Clinical comparative study of sulbactam/ampicillin and imipenem/cilastatin in elderly patients with community-acquired pneumonia |
Q44420238 | Clinical efficacy of imipenem/cilastatin sodium in patients with respiratory tract infections caused by Pseudomonas aeruginosa |
Q44001871 | Clinical efficacy of intravenous doripenem in patients with acute biliary tract infection: a multicenter, randomized, controlled trial with imipenem/cilastatin as comparator |
Q44587546 | Clinical efficacy, safety and tolerability of intramuscular imipenem/cilastatin in the treatment of mild to moderate infections |
Q46313989 | Clinical evaluation of imipenem/cilastatin in the therapy of severe infections in high-risk patients |
Q40722073 | Clinical evaluation of imipenem/cilastatin sodium and fosfomycin as second-line combination chemotherapy in severe infections associated with hematologic disorders |
Q40745950 | Clinical evaluation of imipenem/cilastatin sodium as a second line regimen in severe infections associated with hematologic disorders |
Q43559973 | Clinical evaluation of imipenem/cilastatin sodium in gynecological infection |
Q68671076 | Clinical evaluation of imipenem/cilastatin sodium in infectious complications of hematological malignancies. Tohkai Research Group on Infections in Hematological Disorders |
Q40745955 | Clinical evaluation of imipenem/cilastatin sodium in the internal medicine |
Q44183665 | Clinical evaluation of imipenem/cilastatin sodium in the pediatric field |
Q70266032 | Clinical evaluation of the imipenem/cilastatin combination in the therapy of severe infections in patients with malignant diseases |
Q33458016 | Clinical experience with imipenem/cilastatin: analysis of a multicenter study. |
Q68756753 | Clinical outcome of nosocomial pneumonia following imipenem/cilastatin therapy |
Q35261869 | Clinical pharmacology of imipenem and cilastatin in premature infants during the first week of life |
Q44080894 | Clinical studies of efficacy of imipenem/cilastatin sodium against urinary tract infections with ureterocutaneostomy |
Q40782103 | Clinical studies on imipenem/cilastatin sodium in perinatal use |
Q67929773 | Clinical studies on imipenem/cilastatin sodium in the early therapy of preterm premature rupture of the membrane or threatened abortion and premature delivery |
Q67929774 | Clinical studies on imipenem/cilastatin sodium in the field of obstetrics and gynecology |
Q46953736 | Clinical study of imipenem/cilastatin sodium in children with severe infections |
Q40782098 | Clinical study of imipenem/cilastatin sodium in the perinatal period |
Q44939905 | Clinical study of intramuscular imipenem/cilastatin sodium in the field of obstetrics and gynecology |
Q67869105 | Clinical study of intramuscular imipenem/cilastatin sodium in the field of obstetrics and gynecology |
Q45281507 | Clinical study of the effectiveness of imipenem/cilastatin sodium as the antibiotics of first choice in the expectant management of patients with preterm premature rupture of membranes |
Q54404609 | Clinical trial of imipenem/cilastatin in severely burned and infected patients. |
Q44375965 | Combined effect of clarithromycin and imipenem/cilastatin against urinary biofilm infection after pyeloplasty |
Q43580816 | Combined imipenem/cilastatin and tobramycin therapy of multiresistant Pseudomonas aeruginosa in cystic fibrosis |
Q54795375 | Comparative clinical evaluation of imipenem/cilastatin vs. cefotaxime in treatment of severe bacterial infections. |
Q68088836 | Comparative clinical trial of ceftazidime and imipenem/cilastatin in patients with severe nosocomial pneumonias and septicaemias |
Q54345954 | Comparative efficacy of ciprofloxacin, azlocillin, imipenem/cilastatin and tobramycin in a model of experimental septicemia due to Pseudomonas aeruginosa in neutropenic mice. |
Q68001717 | Comparative neurotoxicity of benzylpenicillin, imipenem/cilastatin and FCE 22101, a new injectible penem |
Q89609405 | Comparative review of imipenem/cilastatin versus meropenem |
Q40601273 | Comparative study of piperacillin/tazobactam versus imipenem/cilastatin in febrile neutropenia (1994-1996) |
Q40670429 | Comparative study of the cost-/effectiveness relationship of initial therapy with imipenem/cilastatin in nosocomial pneumonia. Group study |
Q45127959 | Comparative study of the cost-effectiveness of initial therapy with imipenem/cilastatin in secondary peritonitis |
Q40660341 | Comparison between monotherapy with imipenem/cilastatin sodium (IPM/CS) and combinations of IPM/CS and other drugs for treating bacterial infections in patients with hematopoietic disorders |
Q45580188 | Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation |
Q36406755 | Comparison of efficacy of cefoperazone/sulbactam and imipenem/cilastatin for treatment of Acinetobacter bacteremia. |
Q54651976 | Comparison of imipenem/cilastatin with the combination of aztreonam and clindamycin in the treatment of intra-abdominal infections. |
Q46951637 | Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia |
Q42905606 | Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia |
Q68777079 | Concomitant immunosuppressive and antibiotic therapy--reduction of cyclosporine A blood levels due to treatment with imipenem/cilastatin |
Q42279374 | Correlation between in vitro and in vivo models of proconvulsive activity with the carbapenem antibiotics, biapenem, imipenem/cilastatin and meropenem |
Q43544436 | Cost efficacy of tazobactam/piperacillin versus imipenem/cilastatin in the treatment of intra-abdominal infection |
Q44223071 | Cost-effectiveness of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients |
Q33535030 | Cost-effectiveness of ceftazidime or imipenem/cilastatin versus ceftriaxone + aminoglycoside in the treatment of febrile episodes in neutropenic cancer patients in Germany |
Q73713616 | Cost-effectiveness study of imipenem/cilastatin versus meropenem in intra-abdominal infections |
Q36346133 | Cost-minimization analysis of imipenem/cilastatin versus meropenem in moderate to severe infections at a tertiary care hospital in Saudi Arabia |
Q74619018 | Cost-minimization analysis of piperacillin/tazobactam versus imipenem/cilastatin for the treatment of serious infections: a Canadian hospital perspective |
Q89678458 | Determination of Total and Unbound Meropenem, Imipenem/Cilastatin and Cefoperazone/Sulbactam in Human Plasma: Application for Therapeutic Drug Monitoring in Critically Ill Patients |
Q68746318 | Determination of imipenem and cilastatin in serum and tissue by high-pressure liquid chromatography |
Q39848938 | Determination of imipenem and cilastatin in serum by high-pressure liquid chromatography |
Q72497007 | Determination of imipenem and cilastatin sodium in Primaxin by first order derivative ultraviolet spectrophotometry |
Q39849271 | Disposition of radiolabeled imipenem and cilastatin in normal human volunteers |
Q72909389 | Drug utilization evaluation of imipenem/cilastatin in patients with renal dysfunction |
Q36093598 | Early use of imipenem/cilastatin and vancomycin followed by de-escalation versus conventional antimicrobials without de-escalation for patients with hospital-acquired pneumonia in a medical ICU: a randomized clinical trial |
Q50046889 | Effect of Elevated Imipenem/Cilastatin MICs on Patient Outcomes in Gram-negative Bloodstream Infections. |
Q40689555 | Effect of a combination treatment using imipenem/cilastatin sodium with G-CSF on infections in neutropenic patients with hematological malignancies |
Q54447959 | Effect of imipenem/cilastatin on the colonic microflora. |
Q44732972 | Effect of moxifloxacin versus imipenem/cilastatin treatment on the mortality of mice infected intravenously with different strains of Bacteroides fragilis and Escherichia coli |
Q44103026 | Effectiveness of imipenem/cilastatin (Tienam, MSD) in treating complicated infections in urology |
Q70264573 | Effects of beta-lactam antibiotics imipenem/cilastatin and cefodizime on cellular and humoral immune responses in BALB/c-mice |
Q74628286 | Effects of fosfomycin and imipenem/cilastatin on nephrotoxicity and renal excretion of vancomycin in rats |
Q73469851 | Effects of imipenem and cilastatin on human T-lymphocytes derived from acute leukemia patients with chemotherapy-induced leucopenia: studies of T-lymphocyte responses in the presence of acute myelogenous leukemia (AML) blast accessory cells |
Q54141127 | Efficacy and safety of imipenem/cilastatin in the empirical treatment of septicemia. |
Q39830861 | Efficacy and safety of imipenem/cilastatin: a review of worldwide clinical experience. |
Q33642184 | Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial |
Q33456282 | Efficacy and tolerance of imipenem/cilastatin in the treatment of surgical infections with and without bone involvement |
Q69839257 | Efficacy of imipenem/cilastatin in endocarditis |
Q68751641 | Efficacy of imipenem/cilastatin in patients with severe bacterial infections |
Q54273050 | Efficacy of sodium imipenem/cilastatin on patients of complicated urinary tract infections--following the failure of prior antimicrobial agents |
Q40661480 | Empirical monotherapy with meropenem versus imipenem/cilastatin for febrile episodes in neutropenic patients |
Q59808268 | Erratum for Rhee et al., "Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants" |
Q47392097 | Evaluation and financial impact of imipenem/cilastatin dosing in elderly patients based on renal function and body weight. |
Q28333592 | Evaluation of an imipenem/cilastatin target drug program |
Q50202435 | Evaluation of imipenem/cilastatin against nosocomial infections and multiresistant pathogens |
Q68392435 | Evaluation of imipenem/cilastatin for treatment of infection in an elderly population |
Q40766330 | Evaluation of imipenem/cilastatin sodium in the treatment of respiratory tract infections |
Q35229009 | Evaluation of the appropriateness of imipenem/cilastatin prescription and dosing in a tertiary care hospital |
Q81541341 | Evaluation of the efficacy and safety of imipenem/cilastatin in the treatment of complicated urinary tract infections |
Q54108342 | Evaluation of the efficacy and tolerance of intravenously administered imipenem/cilastatin in the treatment of septicaemia. |
Q68751643 | Experience with imipenem/cilastatin in the intensive care unit |
Q43848037 | Experience with imipenem/cilastatin sodium in the field of obstetrics and gynecology |
Q54206754 | Exposure to imipenem/cilastatin causes nephrotoxicity and even urolithiasis in Wistar rats. |
Q68136446 | Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem/cilastatin |
Q70481355 | First- and second-derivative spectrophotometric determination of imipenem and cilastatin in injections |
Q41758206 | Formulary review of the carbapenems: comparison of imipenem/cilastatin and meropenem |
Q44188273 | Fundamental and clinical studies of imipenem and imipenem/cilastatin sodium in the field of obstetrics and gynecology |
Q40807621 | Fundamental and clinical studies on imipenem/cilastatin sodium in the field of obstetrics and gynecology |
Q43622256 | Fundamental and clinical studies on imipenem/cilastatin sodium in the field of obstetrics and gynecology |
Q44137033 | Fundamental study of imipenem/cilastatin sodium in obstetrics and gynecology |
Q37883801 | Hospitalized patients with community-acquired pneumonia in Hong Kong: a randomized study comparing imipenem/cilastatin and ceftazidime |
Q43435837 | Imipenem and cilastatin in acute osteomyelitis and suppurative arthritis. Therapy in infants and children |
Q44238260 | Imipenem/Cilastatin Drug Utilization Evaluation in a Large Community Hospital |
Q74064105 | Imipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patients with intra-abdominal infections: results of a prospective, randomized, multicentre trial |
Q70125128 | Imipenem/cilastatin (Primaxin): evaluation in general surgical practice |
Q74218096 | Imipenem/cilastatin as empirical treatment of severe infections in compromised patients |
Q44434908 | Imipenem/cilastatin as initial single-agent therapy for infections in cancer patients with neutropenia. |
Q40782113 | Imipenem/cilastatin as initial therapy for febrile neutropenic patients |
Q40781913 | Imipenem/cilastatin as monotherapy in neutropenic patients with fever |
Q69914732 | Imipenem/cilastatin as monotherapy in severe infections: comparison with cefotaxime in combination with metronidazole and cloxacillin. Report from a Norwegian Study Group |
Q43808938 | Imipenem/cilastatin as monotherapy in the treatment of acute or chronic lung infections: clinical efficacy and safety. |
Q68032937 | Imipenem/cilastatin as secondary therapy for bacterial infections |
Q68751646 | Imipenem/cilastatin as secondary therapy for infections in cancer patients |
Q69848463 | Imipenem/cilastatin efficacy evaluated |
Q38841887 | Imipenem/cilastatin encapsulated polymeric nanoparticles for destroying carbapenem-resistant bacterial isolates. |
Q50202098 | Imipenem/cilastatin for pediatric infections in hospitalized patients. |
Q54791146 | Imipenem/cilastatin for the treatment of infections in hospitalized children. |
Q81541391 | Imipenem/cilastatin in a group of obstetrics/gynecological surgical patients |
Q44274507 | Imipenem/cilastatin in acute pulmonary exacerbations of cystic fibrosis |
Q72198502 | Imipenem/cilastatin in the treatment of CAPD peritonitis |
Q39830851 | Imipenem/cilastatin in the treatment of intraabdominal infections: a review of worldwide experience |
Q63359882 | Imipenem/cilastatin in the treatment of obstetric and gynecologic infections |
Q39830855 | Imipenem/cilastatin in the treatment of obstetric and gynecologic infections: a review of worldwide experience |
Q54448592 | Imipenem/cilastatin in the treatment of osteomyelitis. |
Q40816832 | Imipenem/cilastatin in the treatment of serious bacterial infections |
Q67923210 | Imipenem/cilastatin in the treatment of severe hospital infections |
Q51766033 | Imipenem/cilastatin in the treatment of severe nosocomial pneumonia. |
Q40662817 | Imipenem/cilastatin monotherapy as salvage treatment in febrile neutropenic patients |
Q77176679 | Imipenem/cilastatin reduces cyclosporin-induced tubular damage in kidney transplant recipients |
Q37064932 | Imipenem/cilastatin sodium (IPM/CS) as an embolic agent for transcatheter arterial embolisation: a preliminary clinical study of gastrointestinal bleeding from neoplasms |
Q72849499 | Imipenem/cilastatin sodium in the treatment of continuous ambulatory peritoneal dialysis-associated peritonitis |
Q92071599 | Imipenem/cilastatin sodium/relebactam fixed combination to treat urinary infections and complicated intra-abdominal bacterial infections |
Q44603924 | Imipenem/cilastatin therapy for serious bacterial infections. |
Q54141123 | Imipenem/cilastatin therapy for serious infections in neonates and infants. |
Q54448574 | Imipenem/cilastatin therapy of bacteremia. |
Q40795266 | Imipenem/cilastatin therapy of infections in cancer patients |
Q54015568 | Imipenem/cilastatin therapy of serious infections: a U.S. multicenter noncomparative trial. |
Q68588488 | Imipenem/cilastatin treatment of acute infections in AIDS/ARC patients |
Q28328448 | Imipenem/cilastatin treatment of bacterial meningitis in children |
Q68788906 | Imipenem/cilastatin treatment of lower extremity skin and soft tissue infections in diabetics |
Q69975216 | Imipenem/cilastatin treatment of multiresistant Pseudomonas aeruginosa lung infection in cystic fibrosis |
Q40801571 | Imipenem/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: a prospective, randomized multi-clinic study |
Q40801578 | Imipenem/cilastatin versus aminoglycoside plus amoxicillin plus clindamycin in the treatment of serious postoperative infections |
Q40687693 | Imipenem/cilastatin versus ceftazidime-amikacin in the treatment of febrile neutropenic patients |
Q72576304 | Imipenem/cilastatin versus gentamicin/clindamycin for treatment of serious bacterial infections. Report from a Scandinavian Study Group |
Q44419033 | Imipenem/cilastatin versus gentamicin/clindamycin: a cost effectiveness study |
Q41791319 | Imipenem/cilastatin versus piperacillin plus amikacin as empiric therapy in the treatment of febrile episodes in neutropenic patients with haematologic malignancies |
Q40505651 | Imipenem/cilastatin versus piperacillin/tazobactam plus amikacin for empirical therapy in febrile neutropenic patients: results of the COSTINE study |
Q54447773 | Imipenem/cilastatin vs. gentamicin/clindamycin for the treatment of moderate to severe infections in hospitalized patients. |
Q40394880 | Imipenem/cilastatin with or without glycopeptide as initial antibiotic therapy for recipients of autologous stem cell transplantation: results of a Spanish multicenter study. |
Q70391535 | Imipenem/cilastatin, an alternative treatment of pseudomonas infection in cystic fibrosis |
Q68751655 | Imipenem/cilastatin: a multicentre international study of its clinical efficacy, safety and potential as empirical therapy |
Q33560379 | Imipenem/cilastatin: a pharmacoeconomic appraisal of its use in intra-abdominal infections |
Q40675256 | Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections |
Q44146647 | Imipenem/cilastatin: evolution of the sustained-release intramuscular formulation |
Q54448584 | Imipenem/cilastatin: general experience in a community hospital. |
Q39514968 | Imipenem/cilastatin: its use in the treatment of foot infections in the compromised host |
Q68788903 | Imipenem/cilastatin: monotherapy of hospital infections |
Q69839263 | Imipenem/cilastatin: pharmacokinetic profile in renal insufficiency |
Q45011718 | Imipenem/cilastatin: rationale for a fixed combination |
Q39839168 | Imipenem/cilastatin: the first carbapenem antibiotic. |
Q67914128 | Impact of imipenem/cilastatin on cyclosporine metabolism and excretion |
Q70963564 | Impact of imipenem/cilastatin therapy on faecal flora |
Q54448579 | Impact of imipenem/cilastatin therapy on normal fecal flora. |
Q92124941 | Impact of renal impairment and human organic anion transporter inhibition on pharmacokinetics, safety and tolerability of relebactam combined with imipenem and cilastatin |
Q49172635 | In vitro effect of cefodizime, imipenem/cilastatin and co-trimoxazole on dexamethasone and cyclosporin A depressed phagocytosis |
Q40900452 | In vitro effects of meropenem and imipenem/cilastatin on some functions of human natural effector cells. |
Q31462845 | Incidence of seizures in pediatric cancer patients treated with imipenem/cilastatin |
Q67978759 | Increased risk of central nervous system toxicity in patients treated with ciclosporin and imipenem/cilastatin |
Q54415418 | Intramuscular imipenem/cilastatin for treatment of mild and moderately severe bacterial infections. |
Q37268931 | Intramuscular imipenem/cilastatin in multiple-dose treatment regimens: review of the worldwide clinical experience |
Q68239266 | Intramuscular imipenem/cilastatin in the treatment of mild and moderate infections |
Q54083338 | Intramuscular imipenem/cilastatin treatment of upper reproductive tract infection in women: efficacy and use characteristics. |
Q47195583 | Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-lactamase Inhibitor, Dosed in Combination with Imipenem/Cilastatin in Healthy Subjects |
Q49099046 | Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group |
Q44539356 | Laboratory and clinical studies of imipenem/cilastatin sodium in the pediatric field |
Q44442591 | Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: A multicenter, prospective, randomized, open-label study |
Q73254586 | Levofloxacin in the empirical treatment of patients with suspected bacteraemia/sepsis: comparison with imipenem/cilastatin in an open, randomized trial |
Q53933241 | Meropenem (1.5 g/day) is as effective as imipenem/cilastatin (2 g/day) for the treatment of moderately severe intra-abdominal infections. |
Q73417903 | Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit |
Q54005690 | Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. Meropenem Study Group. |
Q54011895 | Meropenem versus imipenem/cilastatin in the treatment of hospitalized patients with skin and soft tissue infections. |
Q54017571 | Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections. |
Q61446678 | Meropenem versus imipenem/cilastatin in the treatment of intraabdominal infections requiring surgery |
Q42628415 | Meropenem versus imipenem/cilastatin in the treatment of sepsis in Chinese patients. |
Q55394352 | Meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in ICU: an open randomised multicentre study. |
Q60854937 | Modification of Natural Immunity in Mice by Imipenem/Cilastatin |
Q60854904 | Modification of acquired immunity in mice by imipenem/cilastatin |
Q73540713 | Multicenter randomized trial comparing meropenem (1.5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia |
Q48659517 | Multicenter study of the clinical efficacy of imipenem/cilastatin for treatment of serious infections |
Q44743775 | Multiple-dose study of imipenem/cilastatin in patients with end-stage renal disease undergoing long-term hemodialysis |
Q73691103 | Neonatal Klebsiella pneumonia sepsis and imipenem/cilastatin |
Q68753078 | Nephroprotective effect of imipenem/cilastatin in reducing cyclosporine toxicity |
Q73136848 | Nephrotoxic and peroxidative potential of meropenem and imipenem/cilastatin in rat and human renal cortical slices and microsomes |
Q42540781 | Neurological complication during imipenem/cilastatin therapy in uraemic patients |
Q28370580 | Neurotoxicity due to imipenem/cilastatin in patients on continuous ambulatory peritoneal dialysis |
Q45193539 | New antimicrobial agent series XXV: imipenem/cilastatin sodium |
Q37106300 | Nonvolatile salt-free stabilizer for the quantification of polar imipenem and cilastatin in human plasma using hydrophilic interaction chromatography/quadrupole mass spectrometry with contamination sensitive off-axis electrospray |
Q54447768 | Open trial of imipenem/cilastatin therapy for serious bacterial infections. |
Q94562077 | Organic anion transporters also mediate the drug-drug interaction between imipenem and cilastatin |
Q69854524 | Penetration of imipenem and cilastatin into cerebrospinal fluid of patients with bacterial meningitis |
Q46122902 | Pharmacoeconomics of piperacillin/tazobactam and imipenem/cilastatin in the treatment of patients with intra-abdominal infections |
Q68788911 | Pharmacokinetic and clinical evaluation of imipenem/cilastatin in children and neonates |
Q44756695 | Pharmacokinetic and clinical evaluations of imipenem/cilastatin sodium in neonates and premature infants |
Q44966538 | Pharmacokinetic and clinical studies of imipenem/cilastatin sodium in the pediatric field |
Q68003079 | Pharmacokinetic and clinical studies on imipenem/cilastatin sodium in neonates and premature infants |
Q70236947 | Pharmacokinetic and clinical studies on imipenem/cilastatin sodium in the perinatal period. A study of imipenem/cilastatin sodium in the perinatal co-research group |
Q69839260 | Pharmacokinetic profile of imipenem/cilastatin in normal volunteers |
Q72893809 | Pharmacokinetic profiles of intravenous imipenem/cilastatin during slow hemodialysis in critically ill patients |
Q68751636 | Pharmacokinetic studies of imipenem/cilastatin in elderly patients |
Q33448527 | Pharmacokinetics and clinical efficacy of imipenem/cilastatin sodium in neonates |
Q44214685 | Pharmacokinetics and tolerance after repeated doses of imipenem/cilastatin in patients with severe renal failure |
Q42019767 | Pharmacokinetics in healthy subjects of FCE 22101 and its acetoxymethyl ester, FCE 22891: effect of co-administration of imipenem/cilastatin on the renal metabolism of FCE 22101. |
Q40445718 | Pharmacokinetics of Imipenem/Cilastatin Burn Intensive Care Unit Patients Undergoing High-Dose Continuous Venovenous Hemofiltration |
Q46209185 | Pharmacokinetics of Imipenem/Cilastatin during Continuous Arteriovenous Hemofiltration |
Q41884287 | Pharmacokinetics of imipenem and cilastatin after their simultaneous administration to the elderly |
Q73261028 | Pharmacokinetics of imipenem and cilastatin during continuous venovenous hemodialysis in patients who are critically ill |
Q39849680 | Pharmacokinetics of imipenem and cilastatin in patients with cystic fibrosis |
Q45245144 | Pharmacokinetics of imipenem and cilastatin in volunteers. |
Q68781836 | Pharmacokinetics of imipenem/cilastatin in neutropenic patients with haematological malignancies |
Q44317435 | Pharmacokinetics of imipenem/cilastatin sodium in children with peritonitis |
Q68555959 | Pharmacokinetics of intravenous imipenem/cilastatin during intermittent haemofiltration |
Q70199366 | Pharmacokinetics of parenteral imipenem/cilastatin in patients on continuous ambulatory peritoneal dialysis |
Q58700555 | Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants |
Q43260800 | Piperacillin/tazobactam versus imipenem/cilastatin for severe diabetic foot infections: a prospective, randomized clinical trial in a university hospital |
Q72951194 | Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intra-abdominal infections |
Q79803938 | Piperacillin/tazobactam vs imipenem/cilastatin in the treatment of nosocomial pneumonia--a double blind prospective multicentre study |
Q43970361 | Prospective randomized comparison of imipenem/cilastatin and cefotaxime for treatment of lung, soft tissue, and renal infections |
Q42558610 | Prospective surveillance of imipenem/cilastatin use and associated seizures using a hospital information system |
Q57238114 | Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections |
Q40187323 | Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections |
Q81541394 | Puerperal infections: experiences with imipenem/cilastatin |
Q40694778 | Randomised study comparing imipenem/cilastatin to ceftriaxone plus gentamicin in cancer chemotherapy-induced neutropenic fever |
Q72400725 | Randomized comparative trial of imipenem/cilastatin versus aminoglycoside plus amoxycillin plus clindamycin in the treatment of severe intra- and post-operative infections |
Q68223453 | Randomized comparison of imipenem/cilastatin and ceftazidime in the empiric therapy of severe abdominal infections. A multicenter study |
Q45162945 | Randomized comparison of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of patients with intra-abdominal infection |
Q67575437 | Randomized multicenter clinical trial with imipenem/cilastatin versus cefotaxime/gentamicin in the treatment of patients with non-life-threatening infections. German and Austrian Imipenem/Cilastatin Study Group |
Q54448558 | Randomized trial of imipenem/cilastatin versus gentamicin and clindamycin in mixed flora infections. |
Q54431827 | Randomized, comparative trial of imipenem/cilastatin and moxalactam in the treatment of serious obstetric and gynecologic infections. |
Q100426435 | Rapid detection method of carbapenemase-producing Enterobacteriaceae by MALDI-TOF MS with imipenem/cilastatin (KB) disc and zinc sulfate solution |
Q44378146 | Rapid imipenem/cilastatin desensitization for multidrug-resistant Acinetobacter pneumonia |
Q69494351 | Reduction of cyclosporin (CSA) nephrotoxicity by imipenem/cilastatin after kidney transplantation in rats |
Q36754535 | Removal of imipenem and cilastatin by hemodialysis in patients with end-stage renal failure |
Q43925387 | Renal tolerance of imipenem/cilastatin and other beta-lactam antibiotics in rats |
Q28345630 | Results of a clinical trial of clinafloxacin versus imipenem/cilastatin for intraabdominal infections |
Q44136341 | Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/clindamycin for intra-abdominal infections |
Q44625981 | Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group |
Q90767936 | Reversible black tongue: A little known side effect of imipenem/cilastatin and evidence for novel mode of action |
Q49061141 | Reversible encephalopathy with photoparoxysmal response during imipenem/cilastatin treatment. |
Q79957074 | Risk factors of superinfection following imipenem/cilastatin therapy in hospitalised patients with acute exacerbations of severe chronic obstructive pulmonary disease |
Q54448564 | Role of imipenem/cilastatin in the treatment of soft tissue infections. |
Q74529484 | Safe use of imipenem/cilastatin in a neonatal intensive care unit |
Q69839270 | Safety and efficacy of imipenem/cilastatin in treatment of complicated urinary tract infections |
Q69888883 | Safety and tolerability of multiple doses of imipenem/cilastatin |
Q37360448 | Safety of imipenem/cilastatin in neurocritical care patients |
Q42198961 | Seizure and tremor occurring in acute leukemia patients treated with imipenem/cilastatin |
Q68751649 | Severe gram-negative infections in neutropenic children cured by imipenem/cilastatin in combination with an aminoglycoside |
Q70767148 | Severe neutropenia in a patient treated with imipenem/cilastatin |
Q43757675 | Single-dose kinetics of imipenem/cilastatin during continuous arteriovenous haemofiltration in intensive care patients. |
Q67296446 | Stability of imipenem and cilastatin sodium in total parenteral nutrient solution |
Q68003090 | Study of imipenem/cilastatin sodium in the perinatal period |
Q43717529 | Susceptibility of clinically isolated bacterial strains to imipenem/cilastatin sodium |
Q70769424 | Synergic activity of imipenem/cilastatin combined with cefotiam against methicillin-resistant Staphylococcus aureus |
Q87707942 | The Effect of Different Carbapenem Antibiotics (Ertapenem, Imipenem/Cilastatin, and Meropenem) on Serum Valproic Acid Concentrations |
Q72558574 | The antimicrobial activity of imipenem/cilastatin and its treatment in critical ill patients with polymicrobial and mixed infection |
Q45246849 | The cost-effectiveness of cefepime plus metronidazole versus imipenem/cilastatin in the treatment of complicated intra-abdominal infection |
Q54419051 | The effect of imipenem/cilastatin on the aerobic faecal flora of children. |
Q44896409 | The effects of phenytoin and phenobarbital on seizures induced by imipenem/cilastatin in rats |
Q68521782 | The efficacy and safety of imipenem/cilastatin in the treatment of severe bacterial infections |
Q39637650 | The efficacy results and safety profile of imipenem/cilastatin from the clinical research trials |
Q93874571 | The penetration of imipenem/cilastatin into ascitic fluid in patients with chronic liver disease |
Q68751658 | The safety profile of imipenem/cilastatin: worldwide clinical experience based on 3470 patients |
Q44436021 | Therapeutic effects of imipenem/cilastatin sodium against severe infections in patients with hematopoietic disorders. Hanshin Infection Study Group |
Q44113179 | Therapeutic efficacy of imipenem/cilastatin sodium on respiratory tract infections in lung cancer patients |
Q43109993 | Therapeutic equivalence of generic imipenem/cilastatin for therapy of infections at Siriraj Hospital. |
Q68173878 | Therapeutic evaluation of imipenem/cilastatin sodium for bacterial infections in patients with hematological diseases |
Q39849300 | Therapy for lower respiratory tract infections with imipenem/cilastatin: a review of worldwide experience |
Q45795512 | Transcatheter arterial embolization using imipenem/cilastatin sodium for tendinopathy and enthesopathy refractory to nonsurgical management |
Q68239275 | Treatment of acute bacterial peritonitis: a trial of imipenem/cilastatin against ampicillin-metronidazole-gentamicin |
Q73424503 | Treatment of complicated intra-abdominal infections: comparison of the tolerability and safety of intravenous/oral trovafloxacin versus intravenous imipenem/cilastatin switching to oral amoxycillin/clavulanic acid |
Q81605710 | Treatment of diabetic foot infection: an open randomised comparison of imipenem/cilastatin and piperacillin/clindamycin combination therapy |
Q68247467 | Treatment of intra-abdominal infections using imipenem/cilastatin |
Q74594160 | Treatment of obstetric and gynecologic infections with meropenem: comparison with imipenem/cilastatin |
Q69840250 | Treatment of pneumonia with imipenem/cilastatin |
Q35533543 | Treatment of severe nosocomial pneumonia: a prospective randomised comparison of intravenous ciprofloxacin with imipenem/cilastatin |
Q70868064 | Treatment of severe pneumonia in hospitalised patients. Results of a multicentre trial comparing i.v. ciprofloxacin with imipenem/cilastatin |
Q40743949 | Treatment of tularemia with imipenem/cilastatin sodium |
Q40734999 | Trimethoprim-Sulfamethoxazole plus Amikacin as First-Line Therapy and Imipenem/Cilastatin as Second Empirical Therapy in Febrile Neutropenic Patients with Hematological Disorders |
Q54083343 | Twice daily intramuscular imipenem/cilastatin in the treatment of skin and soft tissue infections. |
Q90232368 | Unusual Drug Fever Caused by Imipenem/Cilastatin and a Review of Literature |
Q44384585 | Use of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients |
Q91800497 | Use of inhaled imipenem/cilastatin in pediatric patients with cystic fibrosis: A case series |
Q36338191 | Using imipenem and cilastatin during continuous renal replacement therapy |
Q28333946 | Vertigo caused by intravenous imipenem/cilastatin |
Q28369637 | Worsening of myasthenia gravis on treatment with imipenem/cilastatin |
Q72818671 | [A multi-institutional study on the efficacy and toxicity of imipenem/cilastatin sodium in severe infections complicating hematological diseases and cancers in children. Study Group of Infectious Diseases in Pediatric Hematology/Oncology in Hokkaido |
Q67929771 | [A randomized controlled study on imipenem/cilastatin sodium in comparison to aztreonam + lincomycin in treating severe infections in patients with malignant tumors or hematological diseases] |
Q68738167 | [A study on the penetration of imipenem/cilastatin sodium into the female genital tissues] |
Q44274999 | [Antibacterial activity of imipenem/cilastatin (thienam) against agents causing pyoseptic processes] |
Q54782212 | [Bacterial and clinical studies on imipenem/cilastatin sodium in urological infection]. |
Q54374310 | [Bacteriological and clinical evaluations of imipenem/cilastatin sodium in neonates and premature infants]. |
Q68737454 | [Bone concentrations of imipenem after a dose of imipenem/cilastatin] |
Q54245243 | [Chemotherapy with imipenem/cilastatin for severe infections accompanied by malignant hematological disorders]. |
Q68003074 | [Clinical and pharmacokinetic evaluation of imipenem/cilastatin sodium in neonates and young infants] |
Q72154385 | [Clinical effect of the combined therapy of arbekacin and imipenem/cilastatin against methicillin-resistant Staphylococcus aureus] |
Q72734699 | [Clinical effects of imipenem/cilastatin sodium on gynecological infections] |
Q73130799 | [Clinical efficacy of imipenem/cilastatin sodium for respiratory infections in patients with lung cancer] |
Q67929772 | [Clinical evaluation of imipenem/cilastatin sodium against infections in compromised children (malignancy, hematological disease, collagen disease)] |
Q69430048 | [Clinical evaluation of imipenem/cilastatin sodium against severe infections complicated with hematological disorders and solid tumors] |
Q68014795 | [Clinical evaluation of imipenem/cilastatin sodium against severe infections complicating hematological disorders and solid tumors] |
Q70267465 | [Clinical evaluation of imipenem/cilastatin sodium against severe infections in patients with hematopoietic disorders] |
Q68740640 | [Clinical evaluation of imipenem/cilastatin sodium in children] |
Q54425951 | [Clinical evaluation of imipenem/cilastatin sodium in children]. |
Q67869102 | [Clinical evaluation of intramuscular imipenem/cilastatin sodium in surgical infections] |
Q54336947 | [Clinical evaluation of therapy for aspiration pneumonia with imipenem/cilastatin sodium]. |
Q54438048 | [Clinical experience with imipenem/cilastatin in the treatment of severe infections in general surgery]. |
Q68740642 | [Clinical studies on imipenem/cilastatin sodium in pediatric field] |
Q68003103 | [Clinical studies on imipenem/cilastatin sodium in the field of obstetrics and gynecology in the perinatal period] |
Q68738181 | [Clinical studies on imipenem/cilastatin sodium in the field of obstetrics and gynecology] |
Q68003097 | [Clinical studies on imipenem/cilastatin sodium in the perinatal period] |
Q68738148 | [Clinical studies on the effect of imipenem/cilastatin sodium on infections in obstetrics and gynecology. Tissue concentrations and clinical effects] |
Q54241799 | [Clinical study of imipenem/cilastatin sodium in serious infections in critical care medical center]. |
Q68740653 | [Clinical study on imipenem/cilastatin sodium in the field of pediatrics] |
Q54779761 | [Clinical trials of imipenem/cilastatin sodium in the field of obstetrics and gynecology]. |
Q54302125 | [Combined effect of sulbactam/cefoperazone and other antibiotics against clinical isolates of multi-resistant strains. II. In vitro combined effects of sulbactam/cefoperazone with imipenem/cilastatin, cefuzonam, flomoxef, amikacin or tobramycin]. |
Q68740667 | [Concentration of imipenem/cilastatin sodium in bone marrow blood following intravenous drip infusion] |
Q52885046 | [Contribution of imipenem/cilastatin in the treatment of peritonitis: a comparative economic analysis in the case of France] |
Q70198126 | [Do imipenem and cilastatin interfere with the determination of serum creatinine?] |
Q68901491 | [Effect and tolerance of daily 2 X 1 g imipenem/cilastatin in general surgery] |
Q73435815 | [Effect of imipenem/cilastatin combined with vancomycin for MRSA infection] |
Q68740668 | [Effect of imipenem/cilastatin sodium in thirty cases of bone and joint infection] |
Q77320782 | [Efficacy and safety of intramuscular imipenem/cilastatin (IPM/CS) for complicated urinary tract infections] |
Q68778413 | [Efficacy and tolerability of imipenem/cilastatin in infections at various sites] |
Q54252855 | [Efficacy and tolerance of imipenem/cilastatin in the adjuvant treatment of surgery for peritonitis in patients over the age of 70 years] |
Q68003085 | [Evaluation of imipenem/cilastatin sodium in neonatal infections] |
Q73064044 | [Experience in the use of imipenem/cilastatin (thienam) in a surgical clinic] |
Q70015417 | [Fundamental and clinical evaluation of imipenem/cilastatin sodium in the field of pediatrics] |
Q68003100 | [Fundamental and clinical evaluation of imipenem/cilastatin sodium in the perinatal period] |
Q54427166 | [Fundamental and clinical studies of imipenem/cilastatin sodium in the field of obstetrics and gynecology. Study group of imipenem/cilastatin sodium in the field of obstetric and gynecological infections]. |
Q68738163 | [Fundamental and clinical studies of imipenem/cilastatin sodium in the field of obstetrics and gynecology] |
Q68738185 | [Fundamental and clinical studies of imipenem/cilastatin sodium in the field of obstetrics and gynecology] |
Q93538474 | [Fundamental and clinical studies of imipenem/cilastatin sodium in the field of obstetrics and gynecology] |
Q93538478 | [Fundamental and clinical studies of imipenem/cilastatin sodium in the field of obstetrics and gynecology] |
Q93538483 | [Fundamental and clinical studies of imipenem/cilastatin sodium in the field of obstetrics and gynecology] |
Q93538487 | [Fundamental and clinical studies of imipenem/cilastatin sodium in the field of obstetrics and gynecology] |
Q54433806 | [Fundamental and clinical studies on imipenem/cilastatin sodium in pediatrics]. |
Q68738153 | [Fundamental and clinical studies on imipenem/cilastatin sodium in the field of obstetrics and gynecology] |
Q68738196 | [Fundamental and clinical studies on imipenem/cilastatin sodium in the field of obstetrics and gynecology] |
Q93538470 | [Fundamental and clinical studies on imipenem/cilastatin sodium in the field of obstetrics and gynecology] |
Q93538492 | [Fundamental and clinical studies on imipenem/cilastatin sodium in the field of obstetrics and gynecology] |
Q68740657 | [Fundamental and clinical studies on imipenem/cilastatin sodium in the field of pediatrics] |
Q54425949 | [Fundamental and clinical studies on imipenem/cilastatin sodium in the pediatric field]. |
Q68740645 | [Fundamental and clinical studies with imipenem/cilastatin sodium, a new carbapenem antibiotic, in the field of pediatrics] |
Q69619279 | [Hemostatic parameters influenced by imipenem/cilastatin] |
Q69619283 | [Imipenem/cilastatin in surgical intensive medicine] |
Q72880929 | [Imipenem/cilastatin sodium alone or combined with amikacin sulfate in respiratory infections] |
Q77322887 | [Imipenem/cilastatin sodium and other beta-lactams for respiratory tract infections: clinical benefit and treatment days for cure] |
Q68738172 | [Imipenem/cilastatin sodium in the treatment of obstetric and gynecologic infections] |
Q68974050 | [Imipenem/cilastatin: in vitro activity, concentrations in plasma and prostatic adenoma and therapeutic results in patients with complicated urinary tract infections] |
Q72832312 | [In vitro effects of combinations of antibiotics against highly-fosfomycin-resistant, methicillin-resistant Staphylococcus aureus. With special reference to efficacies of combinations of imipenem/cilastatin and cephems] |
Q54046958 | [In vitro interaction of piperacillin and imipenem/cilastatin combined with aminoglycosides against Pseudomonas aeruginosa]. |
Q68727887 | [Kidney tolerance of imipenem and cilastatin] |
Q67958515 | [Laboratory and clinical studies on imipenem/cilastatin sodium plus amikacin sulfate in patients with severe infections complicating hematological disorders] |
Q53972512 | [Meropenem (Merrem) vs imipenem/cilastatin in hospital treatment of intra-abdominal infections. A multicenter study]. |
Q68738175 | [Outline of imipenem/cilastatin sodium] |
Q68738145 | [Penetration of imipenem/cilastatin sodium into the tissues of the female reproductive organs] |
Q73967931 | [Pharmacoeconomics of meropenem versus imipenem/cilastatin] |
Q69531533 | [Pharmacokinetic and clinical evaluation of imipenem/cilastatin sodium in neonates and premature infants. A study of imipenem/cilastatin sodium by a perinatal co-research group] |
Q68738191 | [Pharmacokinetic and clinical studies of imipenem/cilastatin sodium in the field of obstetrics and gynecology] |
Q68003105 | [Pharmacokinetic and clinical studies of imipenem/cilastatin sodium in the perinatal period] |
Q68003077 | [Pharmacokinetic and clinical studies with imipenem/cilastatin sodium in neonates] |
Q68740664 | [Pharmacokinetic and clinical studies with imipenem/cilastatin sodium in the pediatric field. Pediatric Study Group for Imipenem/Cilastatin Sodium] |
Q69654796 | [Pharmacokinetic, bacteriological and clinical studies on imipenem/cilastatin sodium in neonates] |
Q54353993 | [Pharmacokinetic, bacteriological and clinical studies on imipenem/cilastatin sodium in neonates]. |
Q68003087 | [Pharmacokinetics and clinical evaluation of imipenem/cilastatin sodium in pediatric surgery] |
Q72595269 | [Revaluation of current antimicrobials. Series 24: imipenem/cilastatin] |
Q68740661 | [Studies on imipenem/cilastatin sodium in the field of pediatrics] |
Q54374305 | [Studies on imipenem/cilastatin sodium in the perinatal period]. |
Q68885700 | [Study of the intraperitoneal penetration of imipenem/cilastatin in acute peritonitis with perforation] |
Q71295124 | [Study of the usefulness of a kit containing imipenem/cilastatin powder with diluent for injection: accuracy of reconstitution] |
Q71295118 | [Study of the usefulness of a kit containing imipenem/cilastatin powder with diluent for injection: convenience of use and preparation] |
Q77320780 | [The clinical efficacy of imipenem/cilastatin sodium in orthopedic infections and drug levels in the bone tissue] |
Q72188401 | [Thienam (imipenem/cilastatin) as an agent for empirical antibiotic therapy] |
Q70321901 | [Treatment of bronchopulmonary infections in patients during artificial respiration with imipenem/cilastatin] |
Q54149297 | [Treatment of respiratory tract infections with imipenem/cilastatin in critical patients with respiratory insufficiency]. |
Q37155 | World Health Organization Model List of Essential Medicines | has part(s) | P527 |
Arabic (ar / Q13955) | https://ar.wikipedia.org/wiki/اميبينيم/سيلاستاتين | wikipedia |
https://en.wikipedia.org/wiki/Imipenem/cilastatin | wikipedia | |
https://es.wikipedia.org/wiki/Imipenem/cilastatina | wikipedia | |
Persian (fa / Q9168) | https://fa.wikipedia.org/wiki/ایمیپنم/سیلاستاتین | wikipedia |
イミペネム・シラスタチン | wikipedia | |
or | https://or.wikipedia.org/wiki/ଇମିପେନେମ/ସିଲାସ୍ଟାଟିନ | wikipedia |
https://pt.wikipedia.org/wiki/Imipenem/cilastatina | wikipedia | |
https://ro.wikipedia.org/wiki/Imipenem/cilastatin | wikipedia | |
Serbo-Croatian (sh / Q9301) | https://sh.wikipedia.org/wiki/Imipenem/cilastatin | wikipedia |
https://sr.wikipedia.org/wiki/Imipenem/cilastatin | wikipedia | |
https://vi.wikipedia.org/wiki/Imipenem/cilastatin | wikipedia | |
https://zh.wikipedia.org/wiki/亚胺培南/西司他丁 | wikipedia |
Search more.